Hull, UK.
Rome, Italy.
Aliment Pharmacol Ther. 2018 Nov;48(9):941-950. doi: 10.1111/apt.14969. Epub 2018 Sep 18.
Treatment paradigms for Crohn's disease with perianal fistulae (CD-pAF) are evolving.
To study the impact of multimodality treatment in CD-pAF on recurrence rates and the need for re-interventions and to identify predictive factors for these outcomes.
This was a multinational multicentre retrospective cohort study. Multimodality approach was defined as using a combination of medical treatments (anti-TNFs ± immunomodulators ± antibiotics) along with surgical approach (examination under anaesthesia (EUA) ± seton drainage) at diagnosis of CD-pAF. Univariable and multivariable analyses were performed for variables indicative of the need for reintervention.
A total of 253 patients were included. 65% of patients received multimodality approach. Multimodality treatment resulted in complete fistula healing in 52% of patients. Re-intervention was needed in 27% of patients with simple and in 40.3% of those with complex fistula. On multivariable analysis multimodality treatment (OR: 0.35, 95% CI: 0.17-0.57, P = 0.001), seton removal (OR: 0.090, 95% CI: 0.027-0.30, P = 0.0001, therapy with infliximab (OR: 0.19, 95% CI: 0.06-0.64, P = 0.007), and therapy with adalimumab (OR: 0.12, "95% CI: 0.026-0.56, P = 0.007) were predictive of avoiding repeat surgery. Proctitis (OR: 3.76, 95% CI: 1.09-12.96, P = 0.03) was predictive of the need for radical surgery (proctectomy, diverting stoma) while multimodality treatment reduced the need for radical surgery (OR: 0.21, 95% CI: 0.05-0.81, P = 0.02).
Multimodality treatment, anti-TNFs use, and removal of setons after multimodality treatment can result in improved outcomes in CD patients with perianal fistulae and reduce the need for repeat surgery and radical surgery.
伴有肛周瘘管的克罗恩病(CD-pAF)的治疗模式正在不断发展。
研究 CD-pAF 中多模式治疗对复发率和再次干预需求的影响,并确定这些结果的预测因素。
这是一项多中心多国回顾性队列研究。多模式方法的定义是在诊断为 CD-pAF 时,联合使用医学治疗(抗 TNFs±免疫调节剂±抗生素)和手术方法(麻醉下检查(EUA)±挂线引流)。对预示需要再次干预的变量进行单变量和多变量分析。
共纳入 253 例患者。65%的患者接受了多模式治疗。多模式治疗使 52%的患者完全愈合瘘管。单纯瘘管患者中有 27%需要再次干预,而复杂瘘管患者中有 40.3%需要再次干预。多变量分析显示,多模式治疗(OR:0.35,95%CI:0.17-0.57,P=0.001)、挂线移除(OR:0.090,95%CI:0.027-0.30,P=0.0001)、英夫利昔单抗治疗(OR:0.19,95%CI:0.06-0.64,P=0.007)和阿达木单抗治疗(OR:0.12,95%CI:0.026-0.56,P=0.007)可预测避免重复手术。直肠炎(OR:3.76,95%CI:1.09-12.96,P=0.03)可预测需要根治性手术(直肠切除术、转流性造口术),而多模式治疗可降低根治性手术的需要(OR:0.21,95%CI:0.05-0.81,P=0.02)。
多模式治疗、抗 TNFs 的使用以及多模式治疗后挂线的移除可以改善伴有肛周瘘管的 CD 患者的预后,并降低再次手术和根治性手术的需求。